Institution statistics

ELI LILLY AND COMPANY LIMITED - United Kingdom 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:500-600
Total Number of Projects:300-400
2018
Criterium:Position:
Overall Score:800-900
Total Project Funding per Partner:> 1000
Total Number of Projects:400-500
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 35
As coordinator: 0
As participant: 35
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 21.499.055 0 2
2019 0 89.622.191 0 9
2018 0 114.900.369 273.288 7
2017 0 39.402.712 0 5
2016 0 52.175.187 0 7
2015 0 23.464.340 1.245.000 2
2014 0 8.207.244 414.860 2
2011 0 6.000.000 0 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
JANSSEN PHARMACEUTICA NV19
NOVARTIS PHARMA16
PFIZER LIMITED13
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD13
F HOFFMANNLA ROCHE12
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT11
KING'S COLLEGE LONDON10
NOVO NORDISK10
TAKEDA DEVELOPMENT CENTRE EUROPE10
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE9
KATHOLIEKE UNIVERSITEIT LEUVEN8
SANOFIAVENTIS8
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT8
UCB BIOPHARMA8
ASTRAZENECA AB7
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE7
BAYER AKTIENGESELLSCHAFT6
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM6
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER6
SIB INSTITUT SUISSE DE BIOINFORMATIQUE6
STICHTING KATHOLIEKE UNIVERSITEIT6
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL6
UNIVERSITAIR MEDISCH CENTRUM UTRECHT6
ABBVIE INC5
ACADEMISCH ZIEKENHUIS LEIDEN5
ALZHEIMER EUROPE5
BAYER5
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG5
CHARITE UNIVERSITAETSMEDIZIN BERLIN5
EUROPEAN PATIENTS' FORUM5
H LUNDBECK AS5
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN5
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE5
REGION HOVEDSTADEN5
SANOFIAVENTIS DEUTSCHLAND5
UNIVERSITY OF AARHUS5
UNIVERSITY OF DUNDEE5
UNIVERSITY OF NEWCASTLE UPON TYNE5
ACADEMISCH ZIEKENHUIS GRONINGEN4
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS4
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V4
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE4
JDRF INTERNATIONAL4
KAROLINSKA INSTITUTE4
MERCK SHARP & DOHME CORP4
STICHTING VUMC4
THE UNIVERSITY OF EDINBURGH4
THE UNIVERSITY OF LIVERPOOL4
UNIVERSITE DE LAUSANNE4
UNIVERSITEIT MAASTRICHT4
AMGEN LIMITED3
ASTELLAS PHARMA EUROPE BV3
FUNDACIO SANT JOAN DE DEU3
INSTITUT DE RECHERCHES SERVIER3
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN3
LUNDS UNIVERSITET3
MEDIZINISCHE UNIVERSITAET WIEN3
MEDIZINISCHE UNIVERSITAT GRAZ3
MEDIZINISCHE UNIVERSITAT INNSBRUCK3
ORION OYJ3
TAKEDA PHARMACEUTICALS INTERNATIONAL3
TECHNISCHE UNIVERSITAET DRESDEN3
THE HYVE BV3
THE LEONA M AND HARRY B HELMSLEY CHARITABLE TRUST3
THE UNIVERSITY OF EXETER3
THE UNIVERSITY OF MANCHESTER3
UNIVERSITA DI PISA3
UNIVERSITAET ZUERICH3
UNIVERSITAETSKLINIKUM AACHEN3
UNIVERSITAETSKLINIKUM HEIDELBERG3
UNIVERSITE LIBRE DE BRUXELLES3
UNIVERSITY COLLEGE LONDON3
UNIVERSITY OF BIRMINGHAM3
UNIVERSITY OF HELSINKI3
ABBVIE2
ABBVIE DEUTSCHLAND GMBH & CO KG2
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM2
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN2
ARTTIC2
ASTRAZENECA2
BAYER PHARMA2
BIOGEN IDEC LIMITED2
BRISTOLMYERS SQUIBB COMPANY CORP2
CELGENE MANAGEMENT SARL2
CENTRE DE RECHERCHE PUBLIC DE LA SANTE2
CENTRE HOSPITALIER DE LUXEMBOURG2
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
CHRISTIAN ALBRECHTS UNIVERSITAET ZU KIEL2
CHU HOPITAUX DE BORDEAUX2
CONCENTRIS RESEARCH MANAGEMENT2
COVANCE LABORATORIES2
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK2
ELLEGAARD GOTTINGEN MINIPIGS AS2
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE2
EUROPEAN CANCER PATIENT COALITION2
EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS2
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE2
Constancy:

Total number of partners:866

Partner loyalty:
Frequent Partner: (> 2 projects): 406
Rare Partner: 460

Frequent / Rare Partner Ratio: 0.88

Diversity:

Subjects:
Subject:No:
LIFE SCIENCES3
Diversity index:1
Categories:
Category:No:
BIOLOGICAL SCIENCES3

Project overview:

Start dateProjectacronymrolefundingpartners
2020-05-01Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA INNODIA HARVESTparticipant5.999.05540
2020-01-01Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies ImmUniverseparticipant15.500.00026
2019-11-01Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases IDEA-FASTparticipant20.997.52346
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-03-01Efficiently Networking European Neurodegeneration Research NEURONETparticipant1.199.12510
2019-03-01Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts IMMUcanparticipant17.830.00028
2019-03-01CARdiomyopathy in type 2 DIAbetes mellitus CARDIATEAMparticipant6.700.00021
2019-03-01EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells EBiSC2participant4.599.64816
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2019-01-01FAIRplus FAIRplusparticipant3.996.15022
2019-01-01Remote Assessment of Disease and Relapse – Alzheimer’s Disease RADAR-ADparticipant4.999.75716
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-08-01Targeting neuroinflammation to combat pathological pain in neurodegenerative diseases and chronic pain syndromes TOBeATPAINparticipant2.870.3598
2018-06-01The GetReal Initiative GetReal Initiativeparticipant1.750.00017
2018-05-01Hypoglycaemia - REdefining SOLutions for better liVEs Hypo-RESOLVEparticipant13.450.05723
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00048
2018-04-01Improving the care of patients suffering from acute or chronic pain IMI-PainCareparticipant11.225.27140
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-11-01Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUSparticipant15.797.88156
2017-03-01Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 IMPRiNDparticipant4.684.99819
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 TransQSTparticipant8.000.00023
2017-01-01ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 ITCC-P4participant7.370.00021
2016-11-01Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 PHAGOparticipant8.838.00020
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-10-01Models Of Patient Engagement for Alzheimer’s Disease - Sofia ref.: 115985 MOPEADparticipant2.043.00015
2016-09-01Biomarker Enterprise to Attack DKD - Sofia ref.: 115974 BEAt-DKDparticipant15.085.93731
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2016-04-01Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881 RHAPSODYparticipant8.130.00027
2015-11-01Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – Sofia ref.: 115797 INNODIAparticipant17.630.00036
2015-05-01REgeneration of inner ear hair cells with GAmma-secretase INhibitors to regain hearing in patients with sensorineural hearing loss REGAINparticipant5.834.3407
2014-10-01Diagnostic and Drug Discovery Initiative for Alzheimer’s Disease D3I4ADparticipant2.208.8985
2014-02-01Translating neuroimaging findings from research into clinical practice PSYSCANparticipant5.998.34615
2011-11-01Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia CRESTARparticipant6.000.00011
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum